With a systematic problem analysis, model building and fact-finding, Hereditary Angioedema Therapeutic Market report helps businesses in decision-making and managing marketing of goods and services. The data and the information regarding Pharmaceutical industry are taken from reliable sources such as websites, annual reports of the companies, and journals etc. and were checked and validated by the market experts. Hereditary Angioedema Therapeutic Market report provides statistics on the current state of the industry as a valuable source of guidance and direction for companies and investors interested in this market. This is the most relevant, unique, fair and creditable global market research report which suits your business needs.

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hereditary-angioedema-therapeutic-market

Market Analysis: Global Hereditary Angioedema Therapeutic Market

Global hereditary angioedema therapeutic market is expected to rise to an estimated value of USD 4.51 billion by 2026, registering a healthy CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the increased awareness about hereditary angioedema in various regions.

Major Market Competitors/Players

Few of the major competitors currently working in the global hereditary angioedema therapeutic market are Takeda Pharmaceutical Company Limited; CSL Limited; BIOCRYST PHARMACEUTICALS, INC.; Pharming Group N.V.; Ionis Pharmaceuticals;  Novartis AG; CENTOGENE AG; Sanofi; KalVista Pharmaceuticals among others.

Market Definition: Global Hereditary Angioedema Therapeutic Market

Hereditary angioedema is a rare genetic disorder. The common symptoms of the disease are repeated incidents of severe swelling limbs, intestinal tract, face, and airway. This disease is categorized into three categories:  Type I HAE, Type II HAE, Type III HAE. As per NIH Organization report, hereditary angioedema affects almost 1 in 50,000 people. The prevalence rate of Type I is more, which represents almost 85% of cases, the prevalence of Type II is 15% of, and the incidence of Type III is very rare.

Market Drivers:

Favourable reimbursement policies is expected to drive the growth of the market
Increasing cases of the hereditary angioedema in various regions globally is expected to drive the growth of the market
Increasing awareness about diagnosis and treatment of hereditary angioedema is also expected to boost the growth of the market
Increasing focus on developing novel therapeutics is expected to drive the growth of the market

Market Restraints:

Stringent regulatory policies is expected to restrict the growth of the market
High price of medicines, which is restricting the overall adoption of these meters
Misdiagnosis of the disease; this factor is expected to restrict the growth of the market
Segmentation: Global Hereditary Angioedema Therapeutic Market

By Type

Type I HAE
Type II HAE
Type III HAE

By Drug Class

C-1 Esterase Inhibitors
Cinryze
Berinert
Ruconest
Bradykynin B2 Receptor Antagonist
Kallikrein Inhibitors
Others

By Application

Prophylaxis
Treatment

By Route of Administration

Oral
Injectable
IV
Subcutaneous

By End-User

Home Healthcare
Hospitals
Clinics
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Geography

North America
U.S.
Canada
Mexico
Europe
Germany
Italy
U.K.
France
Spain
Netherlands
Belgium
Switzerland
Turkey
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
South Korea
Australia
Singapore
Malaysia
Thailand
Indonesia
Philippines
Rest of Asia-Pacific
South America
Brazil
Rest of South America
Middle East and Africa
Saudi Arabia
Rest of Middle East and Africa

Get TOC of Full Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-hereditary-angioedema-therapeutic-market

Key Developments in the Market:

In August 2018, Shire plc (A subsidiary of Takeda Pharmaceutical Company Limited) received FDA approval for its Takhzyro (lanadelumab-flyo). This is a plasma kallikrein inhibitor (monoclonal antibody). This drug is used in the treatment of hereditary angioedema attacks. This will help the company to create a strong product portfolio
In June 2017, CSL Behring received FDA approval for its Haegarda. This is a C1 esterase inhibitor.  This is a low-volume subcutaneous (SC) C1-esterase inhibitor (C1-INH) replacement therapy used in the treatment of hereditary angioedema (HAE) attacks. This will help in the expansion of the company’s product portfolio

Competitive Analysis

Global hereditary angioedema therapeutic market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of hereditary angioedema therapeutic market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.